Our initial focus is to create in vivo CAR-T therapies. Our approach enables precise, durable CAR-T generation inside the body. These CAR-T treatments leverage a cell-targeted lipid nanoparticle (LNP) to deliver therapeutic payloads directly to immune cells in vivo. This approach has the potential to transform patient treatment, improve patient accessibility and redefine what’s possible in medicine.